Lineage Cell Therapeutics LCTX

$ 0.6 -7.07%

Quarterly report 2024-Q3
added 11-14-2024

Lineage Cell Therapeutics Deferred Revenue 2011-2024 | LCTX

Annual Deferred Revenue Lineage Cell Therapeutics

2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
10.8 M	9.42 M	18.1 M	193 K	45 K	42 K	797 K	572 K	2.95 M	208 K	235 K	401 K	466 K

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
18.1 M	42 K	3.4 M

Quarterly Deferred Revenue Lineage Cell Therapeutics

2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
8.25 M	9.14 M	10.1 M	10.8 M	9.92 M	10.4 M	11 M	9.42 M	12.4 M	15.8 M	14.9 M	18.1 M	975 K	613 K	101 K	193 K	193 K	297 K	193 K	45 K	182 K	45 K	43 K	42 K	42 K	103 K	202 K	309 K	513 K	309 K	309 K	572 K	537 K	572 K	572 K	439 K	439 K	439 K	439 K	208 K	208 K	208 K	208 K	235 K	235 K	235 K	235 K	401 K	401 K	401 K	401 K	204 K	204 K	204 K	204 K

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
18.1 M	42 K	2.78 M